Sangamo Therapeutics
SGMO
SGMO
208 hedge funds and large institutions have $1.09B invested in Sangamo Therapeutics in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 54 increasing their positions, 73 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
26% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 73
37% less call options, than puts
Call options by funds: $18.4M | Put options by funds: $29.3M
Holders
208
Holding in Top 10
5
Calls
$18.4M
Puts
$29.3M
Top Buyers
| 1 | +$46.8M | |
| 2 | +$24.6M | |
| 3 | +$15.5M | |
| 4 |
UBS AM
Chicago,
Illinois
|
+$11.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.6M |
Top Sellers
| 1 | -$44M | |
| 2 | -$21M | |
| 3 | -$19.6M | |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$19.1M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$17.1M |